Around 2,000 women in the UK with an aggressive form of breast cancer
could now benefit from Roche’s Perjeta earlier in the treatment pathway
after regulators expanded the drug’s license.
Perjeta is a first-in-class HER2 dimerisation inhibitor that works
synergistically with Herceptin (trastuzumab) to block cancer cell
survival and growth signals.The drug was initially licensed for previously-untreated advanced
HER2-positive breast cancer, but can now also be used pre-surgery for
locally advanced, inflammatory or early-stage disease at high risk of
recurrence. “There is a need to bring effective medicines to patients with cancer
earlier. Perjeta has already shown the longest survival benefit in
patients with previously untreated advanced HER2-positive breast cancer,
so it is very encouraging to see its authorisation in an earlier
setting in order to further improve the long-term outcomes for patients
with this aggressive disease,” noted Andrew Wardley, consultant in
Medical Oncology at The Christie NHS Foundation Trust who was also
involved in trials of the drug.This site is for information on the various Chemo treatments and Stem Cell Therapies since 1992. This journey became bitter sweet in 2014, with the passing of my beautiful and dear wife. Sherry, had fought Non - Hodgkins Lymphoma(NHL) since 1990, in and out of remissions time and time again. From T-Cell therapies(1990's) to Dual Cord Blood Transplant(2014), she was in Clinical Trials over the years. This site is for informational purpose only and is not to promote the use of certain therapies.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment